A Phase II Study of Iberdomide in People with Multiple Myeloma Who Have Had an Autologous Stem Cell Transplant

Share

Full Title

Phase II Multicenter Trial of Iberdomide as Maintenance Therapy for Multiple Myeloma Patients with Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation or After Salvage Autologous Hematopoietic Cell Transplantation

Purpose

Autologous stem cell transplantation is a standard therapy for multiple myeloma. During this treatment, the stem cells in the body that produce blood are removed and then returned after treatment with chemotherapy. Lenalidomide is a medication given as “maintenance” therapy for multiple myeloma. But for patients who have already had this drug as maintenance treatment before a transplant, there is no standard maintenance therapy after transplantation.

The purpose of this study is to assess the safety and effectiveness of the investigational drug iberdomide as maintenance therapy in people with multiple myeloma who already had autologous stem cell transplantation and have had lenalidomide as maintenance therapy prior to the transplant. Iberdomide is designed to target and destroy proteins that promote the growth of myeloma cells. By destroying these proteins, iberdomide may prevent the cancer from returning or getting worse. It is taken orally (by mouth).

 

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have had an autologous stem cell transplant and had lenalidomide as maintenance therapy prior to transplantation.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for people ages 18-75.

For more information and to ask about eligibility for this study, please contact the office of Dr. Gunjan Shah at 212-639-8356.

Protocol

22-040

Phase

II

Investigator